To get a feel for relative numbers here are some rough estimates. Let's compare the MCAD subtypes Mastocytosis and MCAS.
For Mastocytosis, in western Europe , the prevalence is ~5-13/100,000 (
Epidemiology)
Let us take 10 for easy calculation: (10/100,000)*100% =
0.01%Recent papers have estimated a potential prevalence of MCAS within the 10% - 19% range. Let's take
10%.
RefThe estimated prevalence of the two MCAD disease types differs, roughly, by a factor of
~1000.
Take a look at this diagram again:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003574/figure/F1/The green box with the text
'MCMD without elevated tryptase or MC profileration'. That one is more prevalent than diagnoses depicted by the other colored boxes. And not by a small margin but by a huge one. This algorithmic pathway is being skipped in healthcare while it is your most important one based on prevalency.
I think the reason he made that specific selection of supportive serum measurements (IL-6, IL-31, CCL2, CXCL8) is to cover a wide range of MC activation pathways which are involved in selective mediator release, like these:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3318920/table/T3/ .There are tons of them.